# US 2013/0295087 A1 · Methods of treating chronic pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295087 A1
- Document ID: US20130295087A1
- Status: Published application
- Kind: A1
- Application number: 13/892,121
- Filed: 2013-05-10
- Published: 2013-11-07
- Earliest claimed: 2008-03-04
- Assignees: Labrys Biologics, Inc.
- Applicants: Labrys Biologics, Inc.
- Inventors: Kristian Todd Poulsen; David Louis Shelton; Joerg Zeller; Ian Machin; Laura Corradini
- Web page: https://patentgrep.com/patent/US20130295087A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.

## Claims

### Claim 1

A method of reducing incidence of or treating chronic pain or symptoms of chronic pain in an individual, the method comprising administering to the individual a therapeutically effective amount of an anti-CGRP antagonist antibody.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the medicament is prepared to be peripherally administered.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the medicament is administered peripherally.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the medicament is prepared to be administered orally, sublingually, via inhalation, transdermally, subcutaneously, intravenously, intra-arterially, intra-articularly, peri-articularly, locally or intramuscularly.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the medicament is prepared to be administered subcutaneously or intravenously.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody acts peripherally on administration.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method according to claim 1, wherein the chronic pain is cancer pain, and the cancer pain is not pain due to head cancer or bone cancer.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody has one or more of the following characteristics:
(a) binds to CGRP;
(b) blocks CGRP from binding to its receptor;
(c) blocks or decreases CGRP receptor activation;
(d) inhibits blocks, suppresses or reduces CGRP biological activity;
(e) increases clearance of CGRP; or
(g) inhibits CGRP synthesis, production or release.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody has one or more of the following characteristics:
(i) is a human antibody,
(ii) is a humanized antibody,
(iii) is a monoclonal antibody,
(iv) binds CGRP with a Kd of 50 nM or less (as measured by surface plasmon resonance at 37° C.); or
(v) has a half life in-vivo of at least 7 days.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody specifically binds to the C-terminal region of CGRP.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the anti-CGRP antagonist antibody specifically recognises the epitope defined by the sequence GSKAF.

### Claim at position 15

15-19. (canceled)

### Claim 20 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867.

### Claim 21 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866.

### Claim 22 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody is produced by the expression vectors with ATCC Accession Nos. PTA-6867 and PTA-6866.

### Claim 23 (depends on 1)

The method according to claim 1, wherein the medicament is prepared for peripheral administration by sub-cutaneous or intra-venous injection between once, twice, three or four times per month.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the medicament is prepared for peripheral administration with an antibody concentration of between 5 to 100 mg/ml

### Claim 25 (depends on 1)

The method according to claim 1, wherein the medicament is prepared for peripheral administration with an antibody concentration of between 1 to 100 mg/kg of body weight.

### Claim at position 22

26-28. (canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody is administered separately, sequentially or simultaneously in combination with one or more further pharmacologically active compounds.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

A pharmaceutical composition for reducing incidence of or treating chronic pain or symptoms of chronic pain in an individual, comprising an anti-CGRP antagonist antibody and a pharmaceutically acceptable carrier wherein the composition is prepared to be peripherally administered.

### Claim 34 (depends on 33)

A kit comprising:
(a) a pharmaceutical composition according to claim 33, and
(b) instructions for the peripheral administration of an therapeutically effective amount of said pharmaceutical composition to an individual for reducing incidence of or treating chronic pain or symptoms of chronic pain.
